Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Belzupacap sarotalocan - Aura Biosciences/National Cancer Institute

Next Previous
Drug Profile

Belzupacap sarotalocan - Aura Biosciences/National Cancer Institute

Alternative Names: AU 011; Bel-sar; Belzupacap serotalocan; Light-activated AU-011

Latest Information Update: 18 Aug 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Aura Biosciences; National Cancer Institute (USA)
  • Developer Aura Biosciences
  • Class Antineoplastics; Drug conjugates; Phthalocyanines; Viral proteins
  • Mechanism of Action Cell death stimulants; Photosensitisers; Reactive oxygen species stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Uveal melanoma
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Uveal melanoma
  • Phase I/II Bladder cancer
  • Preclinical Solid tumours

Most Recent Events

  • 11 Aug 2026 Interim efficacy and adverse events data from a phase I/II trial in Bladder cancer released by Aura Biosciences
  • 01 Jun 2026 Aura Biosciences completes enrolment in its phase III Compass trial for Uveal melanoma (Early-stage disease, First-line therapy in the US, Australia, Austria, Belgium, Canada, Czech Republic, France, Germany, Israel, Italy, the Netherlands, New Zealand, Spain and the UK (NCT06007690)
  • 20 May 2026 Belzupacap sarotalocan is still in phase I trials for Bladder cancer in the USA (NCT05483868)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top